Gilead Expands ADC Presence With Tubulis Licensing Deal
Deal Snapshot: Gilead will pay $20m up front to the German biotech to develop an antibody-drug conjugate with a topoisomerase-1 payload meant to address durability and safety challenges.
Deal Snapshot: Gilead will pay $20m up front to the German biotech to develop an antibody-drug conjugate with a topoisomerase-1 payload meant to address durability and safety challenges.